Data as of Nov 21
| +0.4255 / +5.17%|
The 2 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 25.00, with a high estimate of 25.00 and a low estimate of 25.00. The median estimate represents a +188.68% increase from the last price of 8.66.
The current consensus among 2 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.